Share prices of Swiss pharmaceutical company (NYSE: NVS) have climbed more than 10% so far this year. The company focuses on cardiovascular, immunology, neuroscience, solid tumors, and hematology therapies, and in early October completed the spinoff of its generics division, Sandoz, into a separate company.

The spinoff isn't the only change the company has made, as it has trimmed its staff and tightened the focus on its therapies into more profitable areas.

Here are two green flags as to why the stock remains a good buy, as well as one red flag as to why it may not be a good buy right now:

Continue reading

Source Fool.com